# Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
Canonical URL: https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-highlight-voqueznar-vonoprazan-at-ddw-2026-annual-meeting
Ticker: PHAT
Company: Phathom Pharmaceuticals
Source: Phathom Pharmaceuticals
Published: 2026-05-01 12:00 EST
Original Source URL: https://investors.phathompharma.com
## Summary

FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week ® (DDW) 2026

## Article Body
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the Digestive Disease Week ® (DDW) 2026
## Recent Company News
- 2026-05-20 12:00 EST — [Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-highlights-breadth-of-independent-vonoprazan-research-at-digestive-disease-week-2026-annual-meeting) — Source: Phathom Pharmaceuticals
- 2026-05-01 12:00 EST — [Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-highlight-voqueznar-vonoprazan-at-ddw-2026-annual-meeting) — Source: Phathom Pharmaceuticals
- 2026-04-30 10:59 EST — [Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Phathom Pharmaceuticals
- 2026-04-20 12:00 EST — [Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-thursday-april-30-2026) — Source: Phathom Pharmaceuticals
- 2026-04-06 12:00 EST — [Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences) — Source: Phathom Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)